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A B S T R A C T
Background. Direct comparisons of the effectiveness of allopurinol with that of other urate-lowering agents in chronic kidney disease (CKD) populations, as well as guideline recommendations for clinical practice, are lacking. Methods. We constructed a pharmacoepidemiology cohort study by including patients from Taiwan's long-term integrated CKD care program to compare the effectiveness among allopurinol, febuxostat and benzbromarone in reducing the risk of progression to dialysis. A total of 874 patients with hyperuricemia who were newly treated with allopurinol, febuxostat or benzbromarone were included. The primary and secondary outcomes were incident end-stage renal disease (ESRD) and the serum uric acid (SUA) changes from baseline, respectively. The results were analyzed using multiple Cox proportional models adjusted for multinomial propensity scores. For subgroup analyses, we further stratified patients according to whether their latest SUA level reached the therapeutic target. Results. Compared with allopurinol, benzbromarone therapy was associated with a reduced risk of progression to dialysis, the adjusted hazard ratio was 0.50 (95% confidence interval, 0.25-0.99). Patients who received allopurinol or febuxostat exhibited a comparable risk of ESRD [adjusted hazard ratio, 0.99 (0.40-2.44)]. Febuxostat was significantly more potent than allopurinol or benzbromarone in lowering SUA levels in the fully adjusted model. Among patients who reached the therapeutic target, those with febuxostat and benzbromarone initiation had a significantly lower risk of ESRD. Conclusions. In conclusion, compared with conventional allopurinol, febuxostat and benzbromarone may be more effective in reducing the risk of progression to dialysis and in lowering SUA levels in CKD populations.
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I N T R O D U C T I O N
In the current practice guideline, information regarding whether, when and how to optimize serum uric acid (SUA) levels among patients with chronic kidney disease (CKD) remains undetermined, despite the increasing evidence suggesting a potential pathogenic role of SUA in CKD progression [1] [2] [3] . Two recent meta-analyses have revealed the marginal renoprotective benefits of urate-lowering agents (ULAs) among patients with CKD; however, most enrolled studies have compared allopurinol with a placebo or no treatment and have not evaluated hard outcomes from a long-term perspective [2, 3] . Direct comparisons of allopurinol with other ULAs in CKD populations are scarce [3] . Although allopurinol is the most widely used ULA, clinicians remain concerned regarding its potentially lethal, systemic hypersensitivity reactions, particularly in treating hyperuricemia in CKD and elderly patients [4, 5] . This concern can lead to allopurinol underdosing, resulting in ineffective control of hyperuricemia [6, 7] . An alternative drug is febuxostat, a new nonpurine xanthine oxidase (XO) inhibitor, which was approved by the US Food and Drug Administration in 2009 [8] . It is a more selective and potent inhibitor of XO and is mainly metabolized in the liver, with elimination occurring primarily in feces and urine [9] ; therefore, dose adjustment is not required in patients with mild-to-moderate renal impairment or even with advanced CKD [10] . A single-center randomized trial recently demonstrated that febuxostat could slow the decline in estimated glomerular filtration rates (eGFRs) in asymptomatic hyperuricemic patients with Stages 3 and 4 CKD [11] . Nevertheless, evidence from direct comparisons of febuxostat and allopurinol remains lacking.
Since 2003, Sanofi-Synthélabo has withdrawn benzbromarone from the USA and some European markets because of its potential fulminant hepatotoxicity. Despite this safety concern, benzbromarone is commonly prescribed in several countries in South America and Asia including Taiwan, China and Japan [12] . A small-scale observational study in Japan revealed that benzbromarone was well tolerated among patients with CKD and that kidney function was stabilized throughout the therapeutic course [13] . However, the effectiveness of benzbromarone in reversing renal failure in advanced CKD remains unknown. Therefore, in this study, we analyzed a large CKD registry-based cohort to directly compare the effectiveness among allopurinol, febuxostat and benzbromarone in reducing the risk of end-stage renal disease (ESRD).
M A T E R I A L S A N D M E T H O D S

Data source and ethics
An inception cohort study was conducted to investigate the comparative effectiveness of various ULAs on the progression of kidney function. Data were obtained from the China Medical University Hospital (CMUH) pre-ESRD database.
Taiwan's National Health Insurance Administration launched the Integrated Care of CKD project in 2002 and has sharpened its focus on Stages 3b-5 CKD since 2007 [14] . This unique pre-ESRD program offers a multidisciplinary approach that involves nephrologists, renal nursing specialists, pharmacists, healthcare educators and dieticians in designing an individualized comprehensive care plan for the wide range of CKD patients in order to meet the therapeutic goals of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF/KDOQI) guidelines [14, 15] . CMUH joined this program in 2003 and has prospectively enrolled willing patients with CKD consecutively [16] . The CMUH pre-ESRD program currently comprises more than 11 000 participants, with an overall retention rate of 90%. The CKD diagnosis was determined according to the nephrologist's working diagnosis or according to the criteria of the NKF/KDOQI clinical practice guidelines for CKD [15] . Patients in this program were regularly followed up at Weeks 12, 8 and 4 for CKD Stages 3b, 4 and 5, respectively, or when necessary. Biochemical markers of renal injury, including serum creatinine, and SUA levels, as well as the spot urine protein-to-creatinine ratio were measured at least every 12 weeks or more frequently. We then enriched the CMUH pre-ESRD database with CMUH electronic health records (EMRs) containing laboratory tests, prescriptions, diagnoses and procedures.
The study was approved by the Big Data Center of China Medical University Hospital and the Research Ethical Committee/ Institutional Review Board of China Medical University (CMUH105-REC3-068).
Study population
This study identified CKD patients who were newly prescribed allopurinol, febuxostat or benzbromarone after a first laboratory diagnosis of hyperuricemia (SUA >7 mg/dL in men or >6 mg/dL in women) between 1 January 2003 and 31 December 2015. The index date was defined as the date of the first prescription. We excluded all patients who were (i) <20 or >100 years of age, (ii) prescribed any of the studied ULAs within 6 months before the index date, (iii) being treated with more than one of the studied ULAs on the index date, (iv) without follow-up SUA data or (v) diagnosed as having any malignancy within 6 months prior to the index date.
Measurement of SUA levels and kidney function
SUA and serum creatinine levels were measured through a timed-endpoint colorimetric method and the Jaffe rate method (kinetic alkaline picrate), respectively, at the CMUH Central Urate-lowering agents and dialysis Laboratory by using Beckman UniCel V R DxC 800 (Beckman Coulter Inc., Brea, CA, USA).The eGFR was estimated using the abbreviated Modification of Diet in Renal Disease equation [17] . The serum creatinine levels at enrollment were used to define the baseline eGFR and the corresponding CKD stages, according to the following cutoff values: >90, 60-89.9, 30-59.9, 15-29.9 and <15 mL/min/1.73 m 2 . All prospective SUA and eGFR measurements within the included subject were considered until the endpoints.
Primary and secondary outcomes
The primary outcome of this study was dialysis, including hemodialysis and peritoneal dialysis. All individuals were followed from the index date until (i) the earliest episode of dialysis, (ii) the time point of switching to another of the studied ULAs, (iii) loss to follow-up (defined as being 90 days late for the last scheduled appointment), (iv) death or (v) 31 December 2015, whichever occurred first. The secondary outcomes were the changes in SUA levels and eGFRs from the baseline to the end of follow-up. The baseline SUA levels and eGFRs were obtained from the last record prior to the index date, and the last follow-up SUA level and eGFR was obtained from the record maintained right before the end of follow-up (lastobservation-carried-forward approach).
Other demographic variables, comorbidities and potential nephrotoxic medications
Sociodemographic variables collected during the enrollment interview. To capture an individual's health status, we used EMRs to ascertain each patient's comorbidities and to identify any concomitant medication use (e.g. antidiabetic medications, cardiovascular medications and other potential nephrotoxicity agents) within 1 year and 6 months, respectively, prior to the index date.
Statistical analyses
Regarding the distribution of baseline demographic and clinical characteristics according to different ULAs, continuous data are presented as median with interquartile range and were compared using the Kruskal-Wallis test; categorical data are expressed as frequency with percentage and were compared using the chi-square test or Fisher's exact test, as appropriate.
We conducted Cox proportional hazards modeling to evaluate the hazard ratios (HRs) and 95% confidence intervals (CIs) of incident dialysis with different ULAs. To control the confounding effects of different hyperuricemic states, we selected patients who were first prescribed allopurinol as the reference group, rather than simply selecting CKD patients who were not taking any ULA. Although the comparator was chosen carefully, the inherent heterogeneity in the baseline characteristics among the different groups of ULA users may not have been completely controlled. Therefore, we estimated multiple propensity scores for each of the studied drugs through multinomial logistic regression, by considering covariates including age at the index date, sex, smoking status, alcohol consumption, education level, year of entry into the pre-ESRD program, baseline CKD stage, comorbidities, baseline serum eGFR and prebaseline medications. The estimated propensity score was then used as the independent variable in the Cox proportional hazard model to assess the risk of progression to dialysis for different ULAs. This approach can help maximize the statistical efficiency and power of a given sample size. The quarterly averages of the eGFRs were modeled using the semiparametric group-based trajectory model approach to characterize the longitudinal trajectories of the eGFRs during the study period. The trajectory groups were then adjusted in the multivariable models. To account for the possible survival bias due to increased overall mortality in the CKD population, we also performed a competing risk analysis, according to Fine and Gray [18] .
Exploratory subgroup analyses were performed to evaluate potential effect modification. We stratified patients according to (i) sex, (ii) age older or younger than 65 years, (iii) the presence or absence of diabetes, (iv) the presence or absence of hypertension, (v) CKD stage (early versus late), (vi) symptomatic hyperuricemia defined by the use of acetaminophen, colchicine, non-steroid anti-inflammatory drugs (NSAIDs) or steroid 7 days before and after the index day of ULAs, and (vii) whether the SUA level at the end of follow-up was below the diagnostic threshold of hyperuricemia.
We also evaluated the comparative effectiveness of different ULAs in lowering SUA levels; the least-square mean (LSM) and 95% CI difference and percentage change from the baseline were estimated and compared using analysis of covariance, with adjustment for the period between the index date and blood test, estimated propensity scores and eGFR trajectories. All statistical analyses were performed using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).
R E S U L T S
We identified 2683 patients who were prescribed allopurinol, febuxostat or benzbromarone between January 2003 and December 2015. After the exclusion of individuals who did not meet the enrollment criteria, 337 users of allopurinol, 138 users of febuxostat and 399 users of benzbromarone were included in the final analysis ( Figure 1 ). Compared with benzbromarone initiators, patients who received allopurinol or febuxostat therapy were more likely to have advanced CKD or diabetes. Allopurinol and febuxostat initiators both had higher baseline SUA and creatinine levels than did benzbromarone initiators. A significantly higher proportion of allopurinol initiators also concomitantly received oral hypoglycemic agents, insulin, fibrate, diuretics or calcium channel blockers ( Table 1) .
The median follow-up duration was 7.0 months for febuxostat initiators, 13.0 months for allopurinol initiators and 14.6 months for benzbromarone initiators ( Table 2 ). The median values of the mean daily dosage of studied ULAs were 40.0 and 88.9 mg/day in febuxostat and benzbromarone users, respectively, compared with that of 100.0 mg/day in allopurinol users.
The incidence rates of dialysis per 1000 person-years were 128.9 for allopurinol initiators, 122.9 for febuxostat initiators and 23.1 for benzbromarone initiators (Table 2) . Compared with allopurinol, the use of benzbromarone was associated with a reduced risk of progression to dialysis. The crude HR for dialysis was 0.18 (95% CI, 0.10-0.31); the adjusted HR (aHR) was 0.50 (95% CI, 0.25-0.99), after adjustment for baseline multiple propensity scores and eGFR trajectories. No significantly increased risk of progression to dialysis was observed in febuxostat initiators, compared with allopurinol initiators (aHR, 0.99; 95% CI, 0.40-2.44).
The trajectories of SUA levels are shown in Figure 2 . After adjustment for propensity scores and the time from entry to the last SUA measurement before the study censor date, febuxostat exhibited greater potency in lowering SUA levels than did allopurinol or benzbromarone. The adjusted LSM (95% CI) changes in SUA levels from the baseline were À1.49 (95% CI, À1.82 to À1.16) for allopurinol initiators, À3.71 (95% CI, À4.18 to À3.23) for febuxostat initiators and À2.76 (95% CI, À3.03 to À2.49) for benzbromarone initiators (Table 3) . A significantly greater decline in eGFRs was also noticed among allopurinol initiators (aLSM, À4.68; 95% CI, À6.44 to À 2.92), compared with those treated with febuxostat or benzbromarone (Table 3) .
In the subgroup analysis, the use of benzbromarone reduced the risk of ESRD requiring dialysis, particularly among patients with hypertension (aHR, 0.47; 95% CI, 0.22-0.99) or without diabetes (aHR, 0.47; 95% CI, 0.22-0.99; Figure 3 ). Among patients who reached the therapeutic target (SUA 7 mg/dL) defined by the last SUA measurement before censorship, febuxostat and benzbromarone initiators had a considerably reduced risk of dialysis dependence [aHRs for febuxostat and benzbromarone were 0.11 (95% CI, 0.03-0.43) and 0.02 (95% CI, 0.00-0.16), respectively; Figure 3 ]. This finding was robust when using SUA 6 mg/dL as the therapeutic target (data not shown).
D I S C U S S I O N
In this 13-year prospective study of a CKD population, benzbromarone significantly reduced the risk of progression to dialysis in the population, compared with allopurinol. Allopurinol was less potent than febuxostat or benzbromarone in lowering SUA levels, with a median follow-up of 9.5 months. This observation was concordant with the most marked eGFR decline among patients receiving allopurinol, although no statistically significant difference was observed among the three ULAs within this relatively short duration. In the subgroup analysis restricted to patients who reached the therapeutic target (SUA 7 mg/dL), both febuxostat and benzbromarone exhibited significantly superior kidney survival rates compared with allopurinol.
A consensus on treating elevated SUA levels in CKD patients remains lacking. Most bodies of available evidence support the perilous effects of elevated SUA levels on the development of CKD in healthy populations; however, among prevalent CKD patients, most studies could not confirm a significant relationship between SUA levels and the progression to dialysis [19] . More controversially, the debate on whether ULAs confers sustained protection of renal function is ongoing due to inconclusive meta-analysis results [2, 3, 20] . The main issues surrounding these trials include short follow-up periods of up to only 24 months and the lack of long-term renal outcomes. Moreover, ensuring baseline comparability in trials on kidney disease, particularly in terms of baseline kidney function, is difficult. For example, most trials have only used single measures, such as serum creatinine levels or eGFRs, to define baseline kidney function; however, few trials have considered the decline rate of kidney function as a random target. Therefore, a longterm observational study is especially useful for overcoming the aforementioned limitations of clinical trials. In the present study, we capitalized on data from a 13-year registry-based CKD cohort with multiple adjustments for kidney function (e.g. a combination of absolute baseline and post-enrollment eGFR trajectories) to approximate counterfactual comparisons.
In this study, patients who received allopurinol did not demonstrate a significant kidney survival benefit in this long-term
CKD patients with hyperuricemia treated with allopurinol, febuxostat, or benzbromarone between January 2003 and December 2015. The index date was defined as the date of the first prescription. N=2,683
Excluded:
Patients with prescription of study urate-lowing agents within 6 months preceding the index date (n=1,341)
Patients who received more than one kind of urate-lowing agent on the index date (n=144)
Patients without follow-up serum uric acid data (n=163)
Patients with prior diagnoses of any cancer within 6 months preceding the index date (n=161)
FIGURE 1: Flowchart of study selection.
Urate-lowering agents and dialysis prospective cohort (median follow-up, 13 months), compared with those who received febuxostat or benzbromarone. Inadequate dosing of allopurinol may explain the poor effectiveness; because the average defined daily doses for allopurinol, febuxostat and benzbromarone were 0.25, 0.5 and 1.0, respectively, in this cohort. More cautious and conservative prescribing patterns for allopurinol indicate an intense and widespread concern regarding the possible fatal side effects of this medication in this already vulnerable population. By contrast, the use of febuxostat and benzbromarone is attractive because dose adjustment is unnecessary for CKD patients with an eGFR of >20 to 30 mL/ min/1.73 m 2 . Moreover, among patients meeting the target SUA level, febuxostat and benzbromarone consistently demonstrated superior efficacy in halting the progression to dialysis, compared with allopurinol.
In the earliest studies dating back to the1960s, researchers evaluated the role of allopurinol in renal protection among CKD patients [21, 22] . In the 1980s, Gibson et al. reported the first supportive evidence that allopurinol may retard the decline of kidney function in patients with gout [23] . Although recent meta-analyses have described a favorable effect of allopurinol on kidney function, the definite role of ULAs among CKD patients remains an ongoing debate due to the lack of adequately powered randomized studies [2, 3, 20] . Moreover, given the scarcity of comparative trials of allopurinol and other ULAs, the decision between XO inhibitors and uricosurics for hyperuricemic CKD patients is made on an empirical basis. Our study helps in closing this gap but also raises thorny questions. For instance, whether ULAs may provide benefit in maintaining kidney function beyond the urate-lowering effect alone is unknown. Increasing animal studies support the protective role of allopurinol in renal ischemia/reperfusion injury, mainly through the prevention of free radical accumulation [24] . Nonetheless, this modulatory effect has not been consistently observed in randomized trials [25, 26] . The superior effectiveness of febuxostat and benzbromarone in controlling SUA levels and reducing the risk of progression to dialysis that was observed in the current study supports the pathogenic role of uric acid in CKD. The possible additional benefits of febuxostat and benzbromarone beyond their urate-lowering action warrant further investigation. A recent study from Japan linked the capacities of free-radical-trapping and attenuating intraendothelial oxidative stress to benzbromarone [27] . Our findings echo those of Lee et al.'s, who stated that regulatory organizations should re-evaluate the decision to withdraw benzbromarone on the basis of real-world evidence [12] . Nephrologists should be aware of the declining efficacy of benzbromarone among patients with advanced CKD. Moreover, benzbromarone should be used cautiously among patients with nephrolithiasis and over-excretion of uric acid [28] .
Febuxostat may be a reasonable choice for CKD patients as it balances the cost-effectiveness and the risk of acute hypersensitivity syndrome observed with allopurinol or fulminant hepatoxicity observed with benzbromarone [29] . Febuxostat was revealed to be associated with the improvement of cardiac function through the suppression of inflammation [30] . The antiinflammatory effects of febuxostat through XO inhibition and the suppression of arterial reactive oxidative species make it a potential alternative agent for endothelial dysfunction, which is a modifiable factor for the progression of CKD [31, 32] . A few ongoing trials will help to clarify the renoprotective role of febuxostat in patients with CKD [33, 34] .
This study has several limitations. First, this study was performed at a single tertiary medical center that may have had a unique prescribing pattern for ULAs for CKD patients; this may limit the generalizability of our findings. However, the biochemical and pathophysiological similarities across different populations provide additional credibility to the external validity of our findings. Second, the baseline stage of CKD may lead to differential prescription practices for ULAs. For instance, 
FIGURE 2:
Trajectories defined by group-based trajectory modeling of quarterly averaged eGFR across study period from the index date to the study endpoints (n ¼ 789).
nephrologists may be more comfortable in prescribing benzbromarone among patients with mild-to-moderate CKD. In turn, the bias from confounding by indication may lead to an overestimated renoprotective effect of benzbromarone. We addressed this critical challenge by conducting multiple propensity score adjustment, and an optimal balance was achieved across the three treatment groups (Supplementary Table S1 ). Third, in the exploratory subgroup analysis, the number of events in certain categories was insufficient to yield statistically reliable information. Although the propensity adjustment process greatly reduced the risk of over adjustment, the results must be interpreted with caution. Finally, residual confounding could not be completely excluded because propensity score methods only allowed adjustment for observed confounders, and we could not account for unobserved confounding variables such as dietary patterns and the nonprescribed use of nephrotoxic agents.
C O N C L U S I O N
Compared with allopurinol, both febuxostat and benzbromarone may be more effective in lowering SUA levels and reducing the risk of progression to dialysis among CKD patients. The favorable safety profile of febuxostat makes it a particularly ideal option for CKD patients with hyperuricemia. Our findings highlight the urgent need for large comparative randomized trials to confirm these effects and a re-evaluation of the decision to withdraw benzbromarone from the US and European markets.
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